67644 Federal Register / Vol. 62, No. 248 / Monday, December 29, 1997 / Notices

informed consent. Frequency of Response: One-time data collection.

Affected Public: Individuals.

Type of respondents

Estimated

number of

respondents

Estimated

number of

responses

per respondent

Average

burden

hours per

responses

Estimated

total annual

burden

hours requested

Blood Donors .................................................................................................................... 78,000 1 .3333 25,997

The annualized cost to respondents is

estimated at: $259,974 (based on $10 per

hour). There are no Capital Costs to

report. There are no Operating or

Maintenance Costs to report.

Request For Comments

Written comments and/or suggestions

from the public and affected agencies

are invited on one or more of the

following points: (1) Whether the

proposed collection of information is

necessary for the proper performance of

the function of the agency, including

whether the information will have

practical utility; (2) The accuracy of the

agency’s estimate of the burden of the

proposed collection of information,

including the validity of the

methodology and assumptions used; (3)

Ways to enhance the quality, utility, and

clarity of the information to be

collected; and (4) Ways to minimize the

burden of the collection of information

on those who are to respond, including

the use of appropriate automated,

electronic, mechanical or other

technological collection techniques or

other forms of information technology.

Direct Comments To OMB

Written comments and/or suggestions

regarding the item(s) contained in this

notice, especially regarding the

estimated public burden and associated

response time, should be directed to the:

Office of Management and Budget,

Office of Regulatory Affairs, New

Executive Office Building, Room 10235,

Washington, DC 20503, Attention: Desk

Officer for NIH. To request more

information on the proposed project or

obtain a copy of the data collection

plans and instruments contact: Dr.

George J. Nemo, Group Leader,

Transfusion Medicine, Scientific

Research Group, Division of Blood

Diseases and Resources, NHLBI, NIH,

Two Rockledge Centre, Suite 10042,

6701 Rockledge Drive, MSC 7950,

Bethesda, MD 20892–7950, or call nontoll free number (301) 435–0075 or email your request, including your

address to:

nemog@gwgate.nhlbi.nih.gov.

Comments Due Date

Comments regarding this information

collection are best assured of having

their full effect if received on or before

January 28, 1998.

Dated: December 17, 1997.

Sheila E. Merritt,

Executive Officer, NHLBI.

[FR Doc. 97–33745 Filed 12–24–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Cooperative Research and

Development Agreement (CRADA)

Opportunity and/or Licensing

Opportunity for Materials and Methods

for Protection of Tissue From Ischemic

Damage

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The National Institutes of

Health is seeking CRADA partners and/

or licensees for the further development,

evaluation, and commercialization of

materials and methods for protecting

tissues from cell injury by Ischemia. The

invention claimed in U.S. Patent

Application Serial No. 60/053,843,

‘‘12(S)=HpETE (A 12=Lipoxygenase

Metabolite) Significantly Reduces Cell

Injury,’’ is available for licensing (in

accordance with 35 U.S.C. 207 and 37

CFR Part 404) and/or further

development under one or more

CRADAs in several clinically important

applications as described below in the

SUPPLEMENTARY INFORMATION.

DATES: CRADA proposals should be

received on or before March 30, 1998 for

priority consideration. However,

CRADA proposals submitted thereafter

will be considered until a suitable

CRADA Collaborator is selected.

ADDRESSES: CRADA proposals and

questions should be addressed to Dr.

Jonathan Gottlieb, National Heart, Lung,

and Blood Institute, Technology

Transfer Service Center, 31 Center Drive

MSC 2490, Room 1B32, Bethesda,

Maryland 20892–2490; Telephone: 301/

402–5579; Fax: 301/594–3080; E-mail:

GottlieJ@gwgate.nhlbi.nih.gov.

Questions about the licensing

opportunity should be addressed to

Carol Lavrich, Technology Licensing

Specialist, Office of Technology

Transfer, National Institutes of Health,

6011 Executive Boulevard, Suite 325,

Rockville, Maryland 20852–3804;

Telephone 301/496–7735 ext. 287; Fax

301/402–0220; E-mail: Carol—

Lavrich@nih.gov.

SUPPLEMENTARY INFORMATION: Ischemia

and reperfusion injury are significant

causes of tissue damage in diseases and

conditions such as heart attack, stroke

and in organ transplantation. Recently,

scientists at the National Institute of

Environmental Health Sciences and

Duke University, while investigating the

phenomena of preconditioning,

discovered and developed a highly

effective method for protecting tissues

from cell injury by ischemia by use of

12(S)=HpETE.

Previously developed treatments to

prevent ischemic damage are greatly

limited in their effectiveness. TPA,

routinely used to dissolve blood clots,

thereby allowing greater blood flow,

does not prevent ischemic tissue injury.

Aspirin has been shown to have only a

small protective effect in the

cardiovascular system. However, the

above new method demonstrates a

dramatic protective effect—up to 82%

recovery in initial studies—when

administered during injury, as seen in

animal models. The protective effect of

12(S)-HpETE was discovered during

investigation of the 12-lipoxygenaserelated protective effect of ischemic

preconditioning and, unlike other

agents, 12(S)-HpETE has no known

undesirable side effects.

Uses of such an invention may

include treatment of tissue during

angioplasty and treatment of organs

intended for transplantation to limit the

chance of damage.

This research was published in

Circulation Research 76: 457–467, 1995.

Information about the patent

application and pertinent information

not yet publicly described can be

obtained under a Confidential
Federal Register / Vol. 62, No. 248 / Monday, December 29, 1997 / Notices 67645

Disclosure Agreement. Respondees

interested in licensing the invention(s)

will be required to submit an

Application for License to Public Health

Service Inventions. Respondees

interested in submitting a CRADA

proposal should be aware that it may be

necessary to secure a license to the

above patent rights in order to

commercialize products arising from a

CRADA.

Dated: December 16, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 97–33746 Filed 12–24–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Neurological

Disorders and Stroke; Notice of

Meetings

Pursuant to Pub. L. 92–463, notice is

hereby given of meetings of the National

Institute of Neurological Disorders and

Stroke (NINDS).

The National Advisory Neurological

Disorders and Stroke Council and its

subcommittee meetings will be open to

the public as indicated below.

Attendance by the public will be limited

to space available. The meetings will be closed to the

public as indicated below in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

and sec. 10(d) of Pub. L. 92–463, for the

review, discussion and evaluation of

individual grant applications. These applications and discussions

could reveal confidential trade secrets

or commercial property such as

patentable material, and personal

information concerning individuals

associated with the applications, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

Summaries of meetings, rosters of

committee members, and other

information pertaining to the meetings

can be obtained from the Executive

Secretary or the Scientific Review

Administrator indicated. Individuals

who plan to attend and need special

assistance, such as sign language

interpretation or other reasonable

accommodations, should contact the

Executive Secretary listed for the

meeting.

Name of Committee: The Planning

Subcommittee of the National Advisory

Neurological Disorders and Stroke Council.

Date: February 11, 1998.

Place: National Institutes of Health,

Building 31, Conference Room 8A28, 9000

Rockville Pike, Bethesda, MD 20892.

Closed: 1:30 p.m.—recess.

Name of Committee: National Advisory

Neurological Disorders and Stroke Council.

Date: February 12–13, 1998.

Place: National Institutes of Health,

Building 31, Conference Room 6, 9000

Rockville Pike, Bethesda, MD 20892.

Open: February 12, 8:30 a.m.—

approximately 3:00 p.m.

Agenda: A report by the Acting Director,

NINDS; a report by the Director, Division of

Extramaural Activities, NINDS; a report by

the Scientific Director; NINDS; and a

scientific presentation by a NINDS

intramural scientist.

Closed: February 13, approximately 3:00

p.m.—recess; February 14, 8:30 a.m.—

adjournment.

Executive Secretary: Constance W. Atwell,

Ph.D., Director, Division of Extramural

Activities, NINDS, National Institutes of

Health, Bethesda, MD 20892, Telephone:

(301) 496–9248.

The following meetings will be totally

closed to review and evaluate grant

applications:

Name of Committee: National Institute of

Neurological Disorders and Stroke Initial

Review Group (Neurological Sciences and

Disorders A).

Date: February 8–9, 1998.

Time: February 8, 8:30 a.m. to recess;

February 9, 8:30 a.m. to adjournment.

Place: The Enclave Suites, 6165 Carrier

Drive, Orlando, FL 32819.

Contact Person: Dr. Katherine Woodbury,

Scientific Review Administrator, Scientific

Review Branch, NINDS, National Institutes of

Health, Federal Building, Room 9C–10,

Bethesda, MD 20892, (301) 496–9223.

Name of Committee: National Institute of

Neurological Disorders and Stroke Initial

Review Group (Neurological Sciences and

Disorders B).

Date: February 18–20, 1998.

Time: February 18, 7:00 p.m.—recess;

February 19, 8:00 a.m.—recess; February 20,

8:00 a.m. to adjournment.

Place: Crowne Plaza Hotel, 14th and K

Streets, Washington, DC 20005.

Contact Person: Dr. Paul Sheehy, Scientific

Review Administrator, Scientific Review

Branch, NINDS, National Institutes of Health,

Federal Building, Room 9C–10, Bethesda,

MD 20892, (301) 496–9223.

Name of Committee: National Institute of

Neurological Disorders and Stroke Training

Grant and Career Development Review

Committee.

Date: February 20, 1998.

Time: 8:00 a.m. to adjournment.

Place: Wyndham Bristol Hotel, 2430

Pennsylvania Avenue, NW., Washington, DC

20037.

Contact Person: Dr. Alfred Gordon,

Scientific Review Administrator, Scientific

Review Branch, NINDS, National Institutes of

Health, Federal Building, Room 9C–10,

Bethesda, MD 20892, (301) 496–9223.

(Catalog of Federal Domestic Assistance

Program No. 93.853, Clinical Research

Related to Neurological Disorders; No.

93.854, Biological Basis Research in the

Neurosciences).

Dated: December 18, 1997.

LaVerne Stringfield,

NIH Committee Management Officer.

[FR Doc. 97–33747 Filed 12–24–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Division of Research Grants; Notice of

Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings that are being held to review

grant applications:

Study section/contact person February–March 1998

meetings Time Location

AIDS and Related Research Initial Review Group

AIDS & Related Research 1, Dr.

Sami Mayyasi, 301–435–1216.

Mar. 4–5 .................... 8:00 a.m. ................... Hilton Hotel, Palm Springs, CA.

AIDS & Related Research 2, Dr. Gilbert Meier, 301–435–1219.Mar. 13 ...................... 8:00 a.m. ................... Holiday Inn, Chevy Chase, MD.

AIDS & Related Research 3, Dr.

Bruce Maurer, 301–435–1225.

Mar. 4–5 .................... 8:30 a.m. ................... Hilton Hotel, Palm Springs, CA.

AIDS & Related Research 4, Dr.

Mohindar Poonian, 301–435–1218.

Mar. 12–13 ................ 8:30 a.m. ................... Olympia Hotel, Park City, UT.

AIDS & Related Research 5, Dr.

Mohindar Poonian, 301–435–1218.

Mar. 3 ........................ 8:30 a.m. ................... Hyatt Regency Hotel, Bethesda, MD.